Skip to main content

Table 1 Clinicopathologic characteristics of 151 patients

From: Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy

  

Pt. number

%

Sex

M

3

2.0%

 

F

148

98.0%

Age

median

46 years

range 28–70 years

 

≤50

111

73.5%

 

> 50

40

26.5%

Surgery

MRM

120

79.5%

 

BCS

31

20.5%

Histology

ductal

138

91.4%

 

others

13

8.6%

Stage

IIIA

79

52.3%

 

IIIC

72

47.7%

Tumor size

pT ≤ 2 cm

11

7.3%

 

2 < pT ≤ 5

110

72.8%

 

pT > 5 cm

30

19.9%

Involved LNs

4–9

79

52.3%

 

≥10

72

47.7%

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us